Trial Profile

Phase 1 trial of CYT-6091 to treat orphan endocrine cancers of the thyroid and pancreas

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 26 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CYT 6091 (Primary)
Indications Pancreatic cancer; Thyroid cancer
Focus Adverse reactions

Most Recent Events

26 Aug 2022 New trial record
23 Aug 2022 According to a CytImmune Sciences media release, The U.S. National Cancer Institute (NCI) has signed a clinical trial agreement with Cytimmune to conduct this study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com